Institutional investors purchased a net $19.0 million shares of CLDX during the quarter ended December 2012. This may signal that the smart money is gaining interest in this company as the 76.01% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
| Other institutional | 47.54% |
| Mutual fund holders | 28.46% |
| Individual stakeholders | 0.37% |